CTRI/2018/02/011743尚未招募2 期
Experimental and clinical studies on Nagapheni (Opuntia elatior Mill.), an anukta dravya (extra-pharmacopoeial drug), with special reference to its Haematinic activity
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- to increase hemoglobin level
研究概览
简要总结
The patients of age 18 to 70 years anemia with 8-10 g% of Hb% will be enrolled in the study and randommly allocated in two groups.
In one group (n=50) Hatala juice 20 ml two times before meal will given orally for 60 days. In another group (n=50) Tab. Punarnava mandur 2 gm two times with plain water two time s a day for 60 days will given orally before meal. The result will be assessed on the basis of subjective and objective parameter (Hb%). Conclusion will be drawn on the basis of final result
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Patients between age of 18-70 years 2.Patients of both gender 3.Diagnosed cases of Pandu (iron deficiency anaemia) 4.Patients having Hb% in between 8-10 g 5.Patients with reduced RBC count.
排除标准
- •1.Age less than 18 years and more than 70 years.
- •2.Pregnant women and lactating mothers.
- •3.Cases of Chronic Renal (CRF)/ 4.Cases of Chronic Hepatic diseases, Cardiac diseases(CCF) and Cancer 5.Any continuing blood loss e.g., Hematemesis, Melaena, Bleeding piles etc.
- •having Hb% less than 7g% 6.Patients consuming alcohol 7.Patients those are on steroids treatment 8.Patients with treatment of any haematinic drug(Ayurveda/modern) within last two months 9.Minimum wash out period of two months if patients are under previous therapy.
结局指标
主要结局
to increase hemoglobin level
时间窗: To attend 10gm % of Haemoglobinlevel after 2 month of trial drug Opuntia elatior Mill.
次要结局
- to improve QOL of patient(To increase serum ferritin level)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained AnemiaAnemiaNCT01506726Harvey Jay Cohen11
已完成
2 期
Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.Kidney DiseasesAnemiaNCT00210743Johnson & Johnson Pharmaceutical Research & Development, L.L.C.67
已完成
不适用
A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease PatientsChronic DiseaseKidney DiseasesCardiovascular DiseasesNCT00563355Hospital Authority, Hong Kong66
已完成
不适用
Anemia in the ElderlyAnemiaNCT00640172Stanford University343
招募中
1 期
Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain InjuryNeurological DiseasesIschemic StrokeHemorrhagic StrokeAtypical Parkinson DiseaseCerebral PalsyNCT02018406Yonsei University60